Discovery of a novel series of biphenyl benzoic acid derivatives as potent and selective human β3-adrenergic receptor agonists with good oral bioavailability. Part I

Journal of Medicinal Chemistry

Volumn 51, Issue 6, 2008, Pages 1925-1944

  Imanishi, Masashi ^a   Tomishima, Yasuyo ^b   Itou, Shinji ^a   Hamashima, Hitoshi ^a   Nakajima, Yutaka ^a   Washizuka, Kenichi ^a   Sakurai, Minoru ^a   Matsui, Shigeo ^a   Imamura, Emiko ^a   Ueshima, Koji ^a   Yamamoto, Takao ^a   Yamamoto, Nobuhiro ^a   Ishikawa, Hirofumi ^a   Nakano, Keiko ^a   Unami, Naoko ^a   Hamada, Kaori ^a   Matsumura, Yasuhiro ^a   Takamura, Fujiko ^a   Hattori, Kouji ^a  

^a ASTELLAS PHARMA INC   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

2' CHLORO 4' [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]ETHYL] 4' BIPHENYL 4 CARBOXYLIC ACID; 3 (CYCLOHEXYLOXY) 4' [2 [[(2 HYDROXY 2 PHENYLETHYL)AMINO]ETHYL] 4 BIPHENYLCARBOXYLIC ACID; 3 CHLORO 4' [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]ETHYL] 4' BIPHENYL 4 CARBOXYLIC ACID; 4 [4 [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]ETHYL]PHENOXY]BENZOIC ACID; 4' [2 [(2 HYDROXY 2 PHENYLETHYL)AMINO]ETHYL] 3 ISOPROPOXY 4 BIPHENYLCARBOXYLIC ACID; 4' [2 [[(2 HYDROXY 2 PHENYLETHYL)AMINO]ETHYL] 10 ISOBUTYL 4 BIPHENYLCARBOXYLIC ACID; 4' [2 [[(2 HYDROXY 2 PHENYLETHYL)AMINO]ETHYL] 3 ISOBUTOXY 4' BIPHENYL 4 CARBOXYLIC ACID; 4' [2 [[(2 HYDROXY 2 PHENYLETHYL)AMINO]ETHYL] 3 PHENOXY 4' BIPHENYL 4 CARBOXYLIC ACID; 4' [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]ETHYL] 2 FLUORO 4' BIPHENYL 4 CARBOXYLIC ACID; 4' [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]ETHYL] 2 METHOXY 4' BIPHENYL 4 CARBOXYLIC ACID; 4' [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]ETHYL] 2 METHYL 4' BIPHENYL 4 CARBOXYLIC ACID; 4' [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]ETHYL] 2' METHOXY 4' BIPHENYL 4 CARBOXYLIC ACID; 4' [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]ETHYL] 3 (CYCLOHEXYLOXY) 4 BIPHENYLCARBOXYLIC ACID; 4' [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]ETHYL] 3 FLUORO 4' BIPHENYL 4 CARBOXYLIC ACID; 4' [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]ETHYL] 3 ISOBUTOXY 4 BIPHENYLCARBOXYLIC ACID; 4' [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]ETHYL] 3 ISOBUTYL 4 BIPHENYLCARBOXYLIC ACID; 4' [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]ETHYL] 3 ISOPROPOXY 4' BIPHENYL 4 CARBOXYLIC ACID; 4' [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]ETHYL] 3 METHYL 4' BIPHENYL 4 CARBOXYLIC ACID; 4' [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]ETHYL] 4' BIPHENYL 3 CARBOXYLIC ACID; 4' [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]ETHYL] 4' BIPHENYL 4 CARBOXYLIC ACID; 5 [4 [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]ETHYL]PHENYL] 2 THIOPHENECARBOXYLIC ACID; 9 CHLORO 4' [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]ETHYL] 4' BIPHENYL 4 CARBOXYLIC ACID; [4 [4 [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]ETHYL]PHENOXY]PHENOXY]ACETIC ACID; [4' [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]ETHYL] 4 BIPHENYLYL]ACETIC ACID; BENZOIC ACID DERIVATIVE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BIPHENYL DERIVATIVE; CARBACHOL; ISOPRENALINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BLADDER PRESSURE; CONTROLLED STUDY; DOG; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; DRUG SYNTHESIS; FEMALE; NONHUMAN; OVERACTIVE BLADDER; SUBSTITUTION LINE;

ADMINISTRATION, ORAL; ADRENERGIC BETA-AGONISTS; ANESTHESIA; ANIMALS; BENZOIC ACIDS; BIOLOGICAL AVAILABILITY; BIPHENYL COMPOUNDS; BLOOD PRESSURE; CARBACHOL; DOGS; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MODELS, ANIMAL; MOLECULAR STRUCTURE; RECEPTORS, ADRENERGIC, BETA-3; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TIME FACTORS;

EID: 41149138185     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm701324c     Document Type: Article

References (35)

1. 3-adrenergic receptor. Science. 1989, 245, 1118-1121.
2. (a) Arch, J. R. S.; Ainsworth, A. T. Thermogenic and antiobesity activity of a novel β-adrenoceptor agonist (BRL 26830A) in mice and rats. Am. J. Clin. Nutr. 1983, 38, 549-558.
3. (b) Arch, J. R.; Ainsworth, A. T.; Cawthorne, M. A.; Piercy, V.; Sennitt, M. V.; Thod, V. E.; Wilson, C.; Wilson, S. Atypical β-adrenoceptors on brown adpocytes as target for anti-obesity drugs. Nature 1983, 309, 163-165.
4. 3-adrenoceptor-mediated relaxation of the human detrusor. Acta Physiol. Scand. 1998, 164, 117-118.
5. 3- adrenoceptor in the human detrusor muscle. Br. J. Pharmacol. 1999, 126, 819-825.
6. 3- adrenoceptor subtypes in relaxation of the human urinary bladder detrusor: analysis by molecular biological and pharmacological methods. J. Pharmacol. Exp. Ther. 1999, 288, 1367-1373.
7. 3-adrenoceptor in human and rat detrusor muscle. J. Urol. 1999, 16, 680-685.
8. 3-adrenoceptors in human detrusor muscle. Urology 2002, 59 (Suppl 5A), 25-29.
9. (c) Uchida, H.; Shishido, K.; Nomiya, M.; Yamaguchi, O. Involvement of cyclic AMP-dependent and -independent mechanisms in the relaxation of rat detrusor muscle via β-adrenoceptors. Eur. J. Pharmacol. 2005, 518, 195-202.
10. 3-adrenoceptor selective agonist, on relaxation of the human detrusor muscle in vitro. Neurourol. Urodyn. 2006, 25, 815-819.
11. 3-adrenoceptor agonist to treat the overactive bladder. Urol. Clin. N. Am. 2006, 33 (4), 539-543.
12. 3-adrenoceptor agonistic activity of 4′-hydroxynorephedrine derivative as an agent for treatment of frequent urination and urinary incontinence. J. Med. Chem. 2003, 46, 105-112.
13. 3-Adrenoceptor agonists as anti-diabetic and anti-obesity drugs in humans. Curr. Pharm. Des. 2001, 7, 1433.
14. 3- adrenoceptors. Br. J. Clin. Pharmacol. 1996, 42, 291-300.
15. Shuker, A. J.; Bell, M. G.; Bloomquist, W.; Calligaro, D. O.; Cohen, M. L.; Crowell, T. A.; Cusick, T. S.; Drost, C. A.; Evrard, D. A.; Hahn, P. J.; Heiman, M. L.; Jesudason, C. D.; Jones, C. D.; Kim, G.; Kriaucinus, A. V.; Matthews, D. P.; McDonald, J. H.; Neel, D. A.; Palkowitz, A. D.; Peters, M. K.; Rito, C. J.; Siegel, M. G.; Stephens, T. W.; Winter, M. A.; Dananberg, J. 217th ACS National Meeting, Anaheim, CA, U.S.A., 1999,MEDI-159.
16. 3 adrenergic receptor agonist, (R)-N-[4-[2-[[2- hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-[4-[4-(trifluoromethyl) phenyl]thiazol-2-yl]benzenesulfonamide. J. Med. Chem. 2000, 43, 3832-3836.
17. 3-adrenergic receptor agonists. J. Med. Chem. 2006, 49, 2758-2771.
18. 3-adrenergic receptor agonists containing heterobiaryl carboxylic acids. Bioorg. Med. Chem. Lett. 2007, 17, 4670-4677.
19. 3- adrenergic receptor agonists as potential therapeutic agents for obesity and type-II diabetes. Prog. Med. Chem. 2003, 41, 167-189.
20. 3 adrenergic receptor agonists. Curr. Med. Chem. 2006, 13, 25-37.
21. 3 binding selectivity. Bioorg. Med. Chem. Lett. 1997, 7, 1583-1588.
22. 3 adrenergic receptor. Med. Chem. Res. 2000, 10, 164-177.
23. 3 adrenergic receptor agonists containing acylsulfonamide, sulfonyl-sulfonamide, and sulfonylurea carboxylic acid isosteres. J. Med. Chem. 2002, 45, 567-583.
24. 3 adrenergic receptor agonist. Tetrahedron Lett. 1999, 40, 6739.
25. Coutts, S. J.; Adams, J.; Krolikowski, D.; Snow, R. J. Two efficient methods for the cleavage of pinanediol boronate esters yielding the free boronic acids. Tetrahedron Lett. 1994, 35, 5109.
26. (a) Chan, D. M. T.; Monaco, K. L.; Wang, R.-P.; Winters, M. P. New N- and O-arylations with phenylboronic acids and cupric acetate. Tetrahedron Lett. 1998, 39, 2933-2936.
27. (b) Evans, D. A.; Katz, J. L.; West, T. R. Synthesis of diaryl ethers through the copper-promoted arylation of phenols with arylboronic acids. An expedient synthesis of thyroxine. Tetrahedron Lett. 1998, 39, 2937-2940.
28. (c) Decicco, C. P.; Song, Y.; Evans, D. A. Intramolecular O-arylation of phenols with phenylboronic acids: application to the synthesis of macrocyclic metalloproteinase inhibitors. Org. Lett. 2001, 3, 1029-1032.
29. 3 adrenergic receptor agonists, WO2004002939, 2004.
30. (b) Petit, L.; Sonnier, M. Synthesis of 4-(4′-hydroxythiophenyl) phenylethylamine. (Thiotyronamine) and its lower homolog. Bull. Soc. Chim. Fr. 1974, 477-478.
31. (a) A dosing solution containing 8b, 8c, 8d, and 8a was prepared in PEG400, and the dose of each compound was 1.0 mg/kg. After administration of the dosing solution to male rats, dogs, and monkeys, the blood was collected and centrifuged to separate plasma. The plasma samples were analyzed by LC/MS/MS for determination of plasma concentrations of 8b, 8c, 8d, and 8a.
32. (b) Takamura, F.; Tanaka, A.; Takasugi, H.; Taniguchi, K.; Nishio, M.; Seki, J.; Hattori, K. Metabolism investigation leading to novel drug design 2: Orally active prostacyclin mimetics. Part 5. Bioorg. Med Chem. Lett. 2006, 16, 4475-4478.
33. Zhu, C.; Jiang, L.; Chen, T. M.; Hwang, K. K. A comparative study of artificial membrane permeability assay for high throughput profiling of drug absorption potential. Eur. J. Med. Chem. 2002, 37, 399-407.
34. Hurnaus, R.; Reiffen, M.; Sauter, R.; Grell, W.; Rupprecht, E. Preparation of new phenylethanolamines and pharmaceuticals containing them, WO9006299, 1990.
35. Measurements of the concentration of 10a, 10e, and 4 (FK175) in plasma were measured using HPLC or LC/MS.